

Efficacy and safety of L0133 in the treatment of dermatomyositis and polymyositis: prospective, randomised, double-blind, placebo-controlled study

| | | |
|--|--|--|
| Submission date 23/10/2006 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered |
| Registration date 21/12/2006 | Overall study status Completed | <input type="checkbox"/> Protocol |
| Last Edited 01/10/2012 | Condition category Skin and Connective Tissue Diseases | <input type="checkbox"/> Statistical analysis plan |
| | | <input type="checkbox"/> Results |
| | | <input type="checkbox"/> Individual participant data |
| | | <input type="checkbox"/> Record updated in last year |

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Patrick Dupuy

Contact details

ORFAGEN,
CRDPF - LANGLADE
3 avenue Hubert Curien - BP 13562
Toulouse Cedex 1
France
31 035

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Study objectives

Primary objective:

To assess the efficacy of the L0133 product as adjunctive treatment to conventional glucocorticosteroids (GS) and immunosuppressors (IS) in dermatomyositis (DM) and polymyositis (PM) patients with insufficient improvement of muscle strength.

Secondary objective:

To assess the overall safety profile of the intravenous immunoglobulin (IVIg) product in DM and PM patients.

As of 18/01/2008 this record was updated. Changes are written under the relevant sections under the above update date. Please also note that the anticipated end date of this trial has been extended; the initial anticipated end date of this trial was 21/03/2008.

As of 14/08/2009 this record was again updated; all updates can be found under the relevant field with the above update date. At this time, the anticipated end date was also updated; the previous anticipated end date of this trial was 31/08/2009.

As of 09/12/2010 this record was again updated; all updates can be found under the relevant field with the above update date. At this time, the anticipated end date was also updated; the previous anticipated end date of this trial was 31/07/2010.

Please note that as of 01/10/2012, the anticipated end date of this trial was updated from 31/12/2012 to 06/09/2011. This was the final completion date of the study.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Positive opinions from the Ethics Committees in:

1. Austria: approved on 25/01/2007
2. France: approved on 06/03/2006
3. Germany: approved on 18/07/2006
4. Italy: Ancona site approved on 20/07/2006

Added 14/08/2009:

5. Italy: Pisa site approved on 18/09/2008

Added 09/12/2010:

6. Hungary: approved on 21/01/2010
7. Czech Republic: approved on 16/12/2009
8. Mexico: approved on 22/01/2010

Study design

Run-in period: observational study; period I: randomised, double-blind, placebo-controlled, two-parallel groups design; period II: open-labelled, non comparative, one-arm design

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Dermatomyositis (DM) and polymyositis (PM)

Interventions

The study will comprise three periods:

1. Run-in period: observational period, in which patients under conventional therapies (GS, IS) will be followed. Only patients with an insufficient improvement on muscle strength will be allowed to enter Period I.
2. Period I: randomised, double-blind, placebo-controlled, two-parallel groups design (stratification between DM and PM patients).
3. Period II: open-labelled, non comparative, one-arm design.

1. L0133 product: 2 g/Kg (40 ml/Kg) IV per month, delivered in two consecutive days (1 g/Kg daily or 20 ml/Kg daily) during period I and period II
2. Placebo: 40 ml/Kg IV per month, delivered in two consecutive days (20 mL/Kg daily) during period I only

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Prednisone, methotrexate, intravenous immunoglobulin product (L0133)

Primary outcome measure

1. Muscle strength intensity, as defined by the BMRC.
2. Treatment response will be defined as an improvement from baseline of BMRC score at the end of Period I.

Secondary outcome measures

1. Time course evaluation of muscle strength using BMRC index (run-in period, Period I and Period II).

2. Physical function recorded by the patients, as measured by the Health Assessment Questionnaire (HAQ) scale.
3. Visual Analogue Scale (VAS) global disease activity made by the Investigators and the patients
4. Serum activity of muscle enzymes - Measurement outcome as defined by International Myositis Assessment and Clinical Studies Group (IMACS).
5. Cutaneous signs severity, according to the modified three-point scale from Göttfried
6. Other organ involvement (cardiac, pharyngeal, gastro-intestinal, joint, pulmonary, others) assessed by the Investigators, using clinical and paraclinical examinations.
7. Consumption of prednisone during the run-in period, Period I and Period II.
8. Consumption of IS during period II.
9. Routine blood laboratory tests (haematology, chemistry).
10. Adverse events.

Overall study start date

21/09/2006

Completion date

06/09/2011

Eligibility

Key inclusion criteria

Current inclusion criteria as of 14/08/2009:

1. Male or female patients of at least 18 years of age
2. Patients fulfilling the diagnostic criteria (definite or probable) of the European Neuromuscular Committee (ENMC) for idiopathic DM and PM
- 3.1. Patients with an active DM or PM disease who received conventional therapies for at least 14 weeks: oral prednisone 1 mg/kg per day for at least 4 weeks, with or without immunosuppressors (IS), followed by IS at stable dose and prednisone for at least 10 weeks, or
- 3.2. Patients with a contra-indication or a major side-effect to prednisone or methotrexate/other IS, or
- 3.3. Patients under biotherapy with a documented deterioration of their British Medical Research Council (BMRC) score, or
- 3.4. DM patients under biotherapy having a documented deterioration of their cutaneous signs, or
- 3.5. Patients under biotherapy with an onset of visceral involvement
4. Patients with no significant improvement of muscle strength under conventional therapy
5. Patients with BMRC index between 24 and 72 at baseline

Previous inclusion criteria as of 18/01/2008:

1. Male or female patients of at least 18 years of age
2. Patients fulfilling the diagnostic criteria (definite or probable) of the European Neuromuscular Committee (ENMC) for idiopathic DM and PM
3. Patients with an active DM or PM disease who received conventional therapies for at least 14 weeks: oral prednisone 1 mg/Kg per day, immunosuppressors at stable dosage
4. Patients with no significant improvement of muscle strength under conventional therapy, i.e. with an improvement of their muscle British Medical Research Council (BMRC) index of less than 18 points at baseline compared to the beginning of the run-in period
5. Patients with BMRC index between 32 and 64 at baseline

Initial inclusion criteria:

1. Male or female patients of at least 18 years of age
2. Patients fulfilling the diagnostic criteria (definite or probable) of the European Neuromuscular Committee (ENMC) for idiopathic DM and PM
3. Patients with an active DM or PM disease who received conventional therapies for at least 18 weeks: oral prednisone 1 mg/Kg per day, Methotrexate 15 mg per week
4. Patients with no significant improvement of muscle strength under conventional therapy, i.e. with an improvement of their muscle British Medical Research Council (BMRC) index of less than 18 points at baseline compared to the beginning of the run-in period
5. Patients with BMRC index between 32 and 64 at baseline

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

44 patients

Key exclusion criteria

Current exclusion criteria as of 14/08/2009:

1. Pregnant women, nursing mothers and women of childbearing potential with no reliable contraception
2. Patients who do not fulfil the ENMC diagnostic criteria (definite or probable) of idiopathic DM and PM
3. Patients with a diagnosis of paraneoplastic DM or PM
4. Juvenile DM and PM (age less than 18 years)
5. DM patients with no muscle involvement
6. Patients with life expectancy of less than three months
7. Patients whose muscle strength is responsive to conventional therapy, i.e. with an improvement of at least 18 points of their BMRC index at baseline compared to the beginning of the run-in period if BMRC below 40,5 at first run-in period assessment, 12 points if BMRC between 40.5 and 56 included at first run-in period assessment and 8 points if BMRC over 56 at first run-in period assessment
8. Patients with an BMRC index of less than 24 or more than 72
9. Patients having received a bolus of methylprednisone within three weeks prior to study entry
10. Patients with a known allergy to one of the ingredients of the IVIg test product
11. Patients with decompensated cardiac insufficiency or any other inter-current condition that may alter the study conduct
12. Patients with positive Coomb's test at baseline

Previous exclusion criteria as of 18/01/2008:

1. Pregnant women, nursing mothers and women of childbearing potential with no reliable

contraception

2. Patients who do not fulfil the ENMC diagnostic criteria (definite or probable) of idiopathic DM and PM
3. Patients with a diagnosis of paraneoplastic DM or PM
4. Juvenile DM and PM (age less than 18 years)
5. DM patients with no muscle involvement
6. Patients with life expectancy of less than three months
7. Patients with severe forms of DM and PM: pharyngeal, cardiac or pulmonary involvement
8. Patients without conventional treatments as first-line therapy for at least 14 weeks: oral prednisone 1 mg/Kg per day, immunosuppressors at stable dosage
9. Patients whose muscle strength is responsive to conventional therapy, i.e. with an improvement of at least 18 points of their BMRC index at baseline compared to the beginning of the run-in period
10. Patients with a BMRC index of less than 32 or more than 64
11. Patients having received a bolus of methylprednisone within three months prior to study entry
12. Patients with a known allergy to one of the ingredients of the IVIg test product
13. Patients with decompensated cardiac insufficiency or any other inter-current condition that may alter the study conduct
14. Patients with positive Coomb's test at baseline

Initial exclusion criteria:

1. Pregnant women, nursing mothers and women of childbearing potential with no reliable contraception
2. Patients who do not fulfil the ENMC diagnostic criteria (definite or probable) of idiopathic DM and PM
3. Patients with a diagnosis of paraneoplastic DM or PM
4. Juvenile DM and PM (age less than 18 years)
5. DM patients with no muscle involvement
6. Patients with life expectancy of less than three months
7. Patients with severe forms of DM and PM: pharyngeal, cardiac or pulmonary involvement
8. Patients without conventional treatments as first-line therapy: prednisone 1 mg/Kg daily Methotrexate 15 mg per week)
9. Patients whose muscle strength is responsive to conventional therapy, i.e. with an improvement of at least 18 points of their BMRC index at baseline compared to the beginning of the run-in period
10. Patients with a BMRC index of less than 32 or more than 64
11. Patients having received a bolus of methylprednisone within three months prior to study entry
12. Patients with a known allergy to one of the ingredients of the IVIg test product
13. Patients with decompensated cardiac insufficiency or any other inter-current condition that may alter the study conduct
14. Patients with positive Coomb's test at baseline

Date of first enrolment

21/09/2006

Date of final enrolment

06/09/2011

Locations

Countries of recruitment

Austria

Czech Republic

France

Germany

Hungary

Italy

Mexico

Study participating centre

ORFAGEN,

Toulouse Cedex 1

France

31 035

Sponsor information**Organisation**

Orfagen (France)

Sponsor details

CRDPF - LANGLADE

3, avenue Hubert Curien

BP 13562

Toulouse

France

31035

Sponsor type

Industry

Website

<http://www.orfagen.com>

Funder(s)**Funder type**

Industry

Funder Name

Orfagen (France)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration